Vera Therapeutics (NASDAQ:VERA) Shares Gap Up - Should You Buy?

Key Points

• Vera’s Phase 3 ORIGIN 3 results were strong: TRUTAKNA preserved kidney function and reduced the composite risk of kidney disease progression by 76% versus placebo in patients with IgA nephropathy.
• A regulatory filing is planned for Q4 2026 to seek full FDA approval, while early commercial demand has been encouraging with more than 350 patient start forms in the drug’s first 10 weeks.
• Despite the positive data, shares reversed their initial gap-up, reflecting investor caution around accelerated-approval requirements, safety and adoption risks. Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $80.15.

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $34.05, but opened at $37.14. Vera Therapeutics shares last traded at $33.16, with a volume of 3,506,658 shares trading hands.

Vera Therapeutics News Summary

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: Strong ORIGIN 3 results support TRUTAKNA. Vera reported that TRUTAKNA met all prespecified endpoints in the Phase 3 ORIGIN 3 trial for IgA nephropathy. At 52 weeks, the treatment preserved kidney function, with a placebo-adjusted eGFR benefit of 5.6 mL/min/1.73m². Through 104 weeks, the annualized eGFR slope benefit was 5.0 mL/min/1.73m² per year, while the composite risk of kidney disease progression fell 76% versus placebo. Vera kidney drug Trutakna shows strong final results in Phase 3 trial
• Positive Sentiment: Regulatory milestone is planned. Based on the final analysis, Vera plans to submit a supplemental Biologics License Application in the fourth quarter of 2026 seeking full FDA approval, potentially expanding TRUTAKNA beyond its current accelerated approval. Vera's TRUTAKNA Shows Two-Year Kidney Protection; SBLA Planned Q4 2026
• Positive Sentiment: Early commercial demand is encouraging. Vera said it generated more than 350 patient start forms during TRUTAKNA’s first 10 weeks, with paid claims and initially favorable payer policies. The company also described the drug’s safety profile as generally comparable to placebo. Vera Therapeutics Announces TRUTAKNA ORIGIN 3 Results
• Neutral Sentiment: The stock reversed earlier gains and moved lower. The market’s muted response suggests investors may have already anticipated positive trial results or are waiting for detailed data and confirmation of commercial traction. Vera Stock Slides Despite Positive Phase 3 Results
• Negative Sentiment: Approval and safety risks remain. TRUTAKNA’s current indication is still subject to accelerated-approval requirements, so continued approval depends on verification of clinical benefit. Infections occurred in 32% of treated patients versus 28% for placebo, and local administration reactions were more common, creating potential adoption and monitoring concerns.

Analyst Ratings Changes

Several analysts recently commented on VERA shares. Bank of America raised their price objective on Vera Therapeutics from $65.00 to $70.00 and gave the stock a "buy" rating in a research note on Tuesday, July 7th. HC Wainwright decreased their target price on Vera Therapeutics from $125.00 to $90.00 and set a "buy" rating for the company in a research note on Wednesday, August 12th. TD Cowen raised their price target on Vera Therapeutics from $73.00 to $78.00 and gave the stock a "buy" rating in a research report on Wednesday, July 8th. Jefferies Financial Group reiterated a "buy" rating and set a $60.00 price objective on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Finally, Wedbush reissued a "neutral" rating and set a $34.00 target price on shares of Vera Therapeutics in a research note on Monday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $80.15.

Vera Therapeutics Stock Down 2.2%

The firm has a market capitalization of $2.40 billion, a P/E ratio of -5.69 and a beta of 0.96. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.92 and a current ratio of 10.92. The firm's 50-day moving average is $34.99 and its 200 day moving average is $37.09.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($1.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.58) by $0.06. During the same period last year, the company posted ($1.20) earnings per share. As a group, equities research analysts predict that Vera Therapeutics, Inc. will post -6.44 EPS for the current fiscal year.

Insider Transactions at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $35.12, for a total value of $649,720.00. Following the sale, the chief executive officer owned 235,244 shares of the company's stock, valued at approximately $8,261,769.28. This trade represents a 7.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 83,250 shares of company stock valued at $3,307,800. 15.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Vera Therapeutics

Large investors have recently bought and sold shares of the company. Optimize Financial Inc grew its stake in Vera Therapeutics by 1.5% in the fourth quarter. Optimize Financial Inc now owns 17,800 shares of the company's stock valued at $901,000 after purchasing an additional 256 shares in the last quarter. Intech Investment Management LLC raised its stake in shares of Vera Therapeutics by 2.4% during the 4th quarter. Intech Investment Management LLC now owns 17,838 shares of the company's stock worth $903,000 after purchasing an additional 424 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Vera Therapeutics by 12.3% during the 2nd quarter. Arizona State Retirement System now owns 11,813 shares of the company's stock worth $507,000 after purchasing an additional 1,295 shares in the last quarter. ADAR1 Capital Management LLC boosted its holdings in shares of Vera Therapeutics by 8.8% in the 1st quarter. ADAR1 Capital Management LLC now owns 16,033 shares of the company's stock valued at $645,000 after buying an additional 1,300 shares during the last quarter. Finally, ProShare Advisors LLC boosted its holdings in shares of Vera Therapeutics by 16.8% in the 4th quarter. ProShare Advisors LLC now owns 12,938 shares of the company's stock valued at $655,000 after buying an additional 1,864 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company's stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company's research is centered on therapies designed to address the underlying causes of autoimmune conditions rather than primarily managing their symptoms.

Vera's leading product candidate is atacicept, an investigational biologic designed to inhibit two proteins involved in the survival and activity of antibody-producing immune cells, B-cell activating factor and a proliferation-inducing ligand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.